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use#LAAI. Introduction
For many people in the United States the idea of alternative or unconventional medicine conjures up visions
of snake oil salesmen or crazy crystal-bearing shamen. Such images contribute to the gut reaction that
alternative medicine is bunk. Recently, however, Americans have taken increasingly active roles in their
own health care and, in the process, have discovered the potentials of alternative medicine. This growing
fascination with alternative medicine is evidenced by the recent deluge of books, magazines, web sites, health
stores, and clinics dedicated to its practice and development.
The perception that alternative medicine cannot be reconciled with conventional medicine and science belies
both the enchantment with unconventional therapies as well as the distrust of them. In 1993 Congress,
however, decided that America should take a more scientic look at alternative medicine and established
within the Oce of the Director of the National Institutes of Health (NIH) the Oce of Alternative Medicine
(OAM). The function of the OAM is to facilitate the evaluation of alternative medical treatment modalities,
including acupuncture and Oriental medicine, homeopathic medicine, and physical manipulation therapies.1
Congress's establishment of this oce signals a recognition of alternative medicine as more than mere quack-
ery and as a potential source of legitimate health care for many Americans.
Because the Food and Drug Administration (FDA) is the regulatory body with the most powerful inuence
over the health of the American population, how the Agency addresses alternative medicine will be central
to developing the role that it plays in American health care. So far, however, FDA has not demonstrated
foresight in this area. Through its actions, inactions, ocial statements, and propaganda, FDA has displayed
142 U.S.C.A. x283g (1997).
1a simple lack of coherent policy toward alternative medicine. Part of FDA's failure to develop meaningful
policy on alternative medicine stems from its failure to consider alternative medicine in a realistic way. As
a result, FDA has been ineective in contributing to the goal that alternative medicine be a safe and viable
health care option for Americans. Section II sets forth the proposition that alternative medicine demands
serious and immediate attention from FDA. Section III provides a discussion of the ways in which FDA
has failed think about alternative medicine in a realistic way and the reasons why its current regulatory
framework is unworkable for alternative medicine. Section IV presents FDA's inchoate policies toward
alternative medicine and examines their impact on the development of alternative medicine in American
health care. Section V proposes that FDA create exibility within its conventional regulatory scheme to
facilitate the goal of making alternative medicine a safe viable health care choice in the U.S.
II. Why FDA Must Seriously Address Alternative Medicine.
With pressing concerns like cancer, AIDS, breast implants, and bovine growth hormones to attend to, why
should FDA commit time and resources to addressing alternative medicine, a seemingly fringe activity with
limited threats to pubic safety? The answer is two-fold. First, a signicant portion of the American popula-
tion uses alternative medicine. Obviously, the more widespread the use of unconventional therapies, the more
widespread the eects, whether benecial or harmful. Second, unconventional medicine has the potential to
contribute to health care cost containment.
A. Alternative Medicine Has a Major Presence in the United States.
2Although alternative medicine may appear to be on the fringes of health care, recent evidence indicates that it
plays a role in the lives of a signicant portion of the American population. In a widely cited study published
in the New England Journal of Medicine, researchers determined that the frequency of use of alternative
medicine in the United States was signicantly greater than previously believed2. In 1990 approximately
34% of Americans used at least one unconventional therapy3. Of these individuals approximately one-third
visited alternative health care providers for that therapy4. These visits to alternative health care providers
totalled 425 million, which is noticeably greater than the 388 million visits to all U.S. primary care physi-
cians5. Expenditures on alternative therapies totalled $13.7 billion, 75% of which was paid out of pocket
($10.3 billion)6. These out-of-pocket payments can hardly be considered insignicant when compared with
the $12.8 billion spent out of pocket annually for all hospitalizations in the U.S.7
This study also found that the highest use of unconventional medicine was by non-black persons between the
ages of twenty-ve and forty-nine with relatively more education and higher incomes.8 The unconventional
medicines were most commonly used for chronic, non-life-threatening, medical conditions.9 Eighty-three
percent of the people who used alternative therapies also sought treatment from a medical doctor.10 Seventy-
three percent, however, did not tell their medical doctors that they were using unconventional therapies,
creating obvious drug interaction concerns.11
2David M. Eisenberg et al., Unconventional Medicine in the United States{Prevalence, Costs, And Patterns of Use (Special
Article), The New England Journal of Medicine, January 28, 1993, at 246-252.
3This study dened unconventional therapies as: [M]edical interventions not taught widely at U.S. medical schools or
generally available at U.S. hospitals. Examples include acupuncture, chiropractic, and massage therapy. Id.
4Id.
5Id.
6Id.
7Id.
8Id.
9Id.
10Id.
11Id.
3Alternative medicine, with both its benets and risks, has clearly established itself in the lives and bodies
of many Americans. As the major regulatory force this area, FDA has a responsibility to recognize and
consider its role in the development of unconventional therapies. Specically, FDA must handle alternative
medicine in a way that will maximize the benets to users, while minimizing the safety risks.
B. Alternative Medicine as an Ingredient of Health Care Reform.
As the search for a solution to the health care crisis in America continues, alternative medicine has been
touted as one way to alleviate some of the high costs of health care. Part of Congress's motivation in passing
the Dietary Supplement Health and Education Act of 1994 (DSHEA)12, was the potential benet of alterna-
tive medicine to the health of Americans. A stated purpose of the Act is to improve the health status of the
people of the United States and help constrain runaway health care spending by ensuring that the Federal
Government erects no barriers that impede the ability of consumers to improve their nutrition through the
free choice of safe dietary supplements.13
Because FDA's control over dietary supplements prior to the act threatened their availability for use, pas-
sage of DSHEA was considered an important victory for supporters of alternative medicine, which relies
heavily on many of the products that fall under the Act. As explained in the Senate Committee Report,
DSHEA was prompted by ndings that, [T]he importance of nutrition and the benets of dietary supple-
ments to health promotion and disease prevention have been documented increasingly in scientic studies;
there is a denitive link between the ingestion of certain nutrients or dietary supplements and the prevention
of disease; and healthful diets may mitigate the need for expensive medical procedures.14 Specically, the
12Dietary Supplement Health and Education Act of 1994, 103 P.L. 417, 108 Stat. 4325 (1994).
13Id.
14Senate Committee on Labor and Human Resources, Dietary Supplement Health and Education Act of 1994, S. Rep. No.
4Committee Report found, [P]reventive health measures, including education, good nutrition and appropriate
use of safe dietary supplements will limit the incidence of chronic diseases and reduce long-term health care
expenditures; and that reduction in health care expenditures is of paramount importance to the future of
the country and its economic well-being, since the country will spend over one trillion dollars on health care
in 1994.15
Alternative medicine and dietary supplements, in particular, may assist in health care cost containment
in two ways: disease prevention and self-care16. As Robert S. McCaleb of the Herb Research Foundation
testied:
Opinions dier about the [preventive] value of supplements, and it may take years to sort out 'the
truth'. In the meantime, supplements must be sold without disclosing what is already known about
their eects... Millions of [Americans] are willing to spend their own resources on protecting their heath
through diet, exercise and supplements. They are not charging their herbs and vitamins to insurance
companies or Medicaid. They are taking personal responsibility for their health care and attempting to
practice preventive medicine, just as they should. Under the current [pre-DSHEA] regulatory system,
this can be hard to do.17
Because herbal medicines and other forms of alternative medicine have signicant potential to help reduce
health care costs, as Congress has recognized, FDA must take into serious consideration how its activities
will promote or discourage realization of that potential.
III. FDA's Unrealistic View of Alternative Medicine and the Regulatory Implications
A. What Is Alternative Medicine?
410, 103d Cong., 2d Sess. (1994) [hereinafter DSHEA Report].
15Id.
16Rational Regulation of Herbal Products: Testimony Before the Subcomm. on Health and the Environment of the House
Comm. on Energy, Health and the Environment, 102d Cong. (July 29, 1993)(testimony of Robert S. McCaleb, Herb Research
Foundation).
5Alternative medicine is sometimes described as any medical practice or intervention that: *lacks sucient
documentation of its safety and eectiveness against specic diseases and conditions * is not generally taught
in U.S. medical schools * is not generally reimbursable by health insurance providers.18 While the broadness
of this denition is understandable, it is important to remember that such a denition encompasses an expan-
sive spectrum of practices, from traditional Chinese medicine to biofeedback to ozone generators to crystal
healing. For purposes of regulatory analysis, I will divide this broad denition of alternative medicine into
the following categories: (1) systems of medicine, (2) specic therapies that are unapproved, but not related
to Category (1), (3) relatively harmless practices, and (4) phony alternative medicines. These categories will
help to clarify the relevant issues surrounding alternative medicine.
Included in Category (1) are the mostly self-sucient bodies of medicine that are alternative in the sense
they are premised on philosophies that are dierent from those of conventional American medicine. This is
the most promising category of alternative medicine because it covers systems of care that are the conven-
tional medicines of other cultures or widely practiced by certain segments of the U.S. population. As Senate
Minority Leader Tom Daschle, an important proponent of alternative medicine, pointed out, Between 70 and
90 percent of the health care practiced in this world is considered 'alternative' by FDA standards.... In fact,
many of the treatments now recognized as 'conventional' by FDA were once considered 'alternative.'19 This
statement correctly recognizes the cultural biases inherent in perceptions of acceptable versus unacceptable
forms of medicine.
18Isadora B. Stehlin, An FDA Guide to Choosing Medical Treatment, FDA Consumer, June 1995, at 10 [hereinafter Guide].
19Medical Treatment: Testimony Before the Senate Labor & Human Resources Comm., 105th Cong. (July 30, 1996)(testi-
mony by Senate Democratic Leader Tom Daschle).
6Among the most accepted bodies of medicine in this category in the U.S. are osteopathic manipulative
therapy (OMT)20, homeopathy21 and chiropractic22. Although the reputation of these medicines is lightly
tainted by visions of quackery, they represent the major systems of alternative care in the U.S.
Hardly considered alternative in other cultures, traditional Chinese medicine (TCM)23 and Ayurveda24 (tra-
ditional Indian medicine) also belong in this category. Both TCM and Ayurveda rely on a vast herbal
pharmacopoeia.25 Related to these medicines is the more general practice of herbal medicine, which uses a
variety of herbs in various forms to prevent and treat a wide range of diseases. The medicines that should
fall into Category (1) tend to be both preventive and curative in nature, but also view health in a more
holistic, integrated way. As a result the line between medicine and lifestyle grows rather tenuous.
Category (2) alternative medicines include very specic therapies that are not yet (or will never be) approved
by FDA. Many of these are drugs or devices that are just too new to be approved. Some will pass through
20OMT is based on the principle of manipulating the body mechanically to allow the circulatory and nervous systems to bring
natural healing powers to ailing parts of the body. Most osteopaths today, however, do not use manipulation as the primary
method of treatment; instead they rely on the same drugs and surgery used by medical doctors. Andrew Weil, Spontaneous
Healing 29 (Alford A. Knopf 1995).
21Established 200 years ago, homeopathic medicine is based on the theory that like treats like. Because the remedies are
so highly diluted, they pose insignicant threats to safety. The dilutions are supposed to work on the body's energy eld,
catalyzing natural healing responses, but critics maintain that they are purely placebos. Id. at 244.
22Chiropractic, which uses spinal adjustment to cure ailments, was established a century ago and has had a history of
being attacked as quackery. In 1971 the American Medical Association's Committee on Quackery declared as its 'primary
mission'...'rst, the containment of chiropractic, and, ultimately, the elimination of chiropractic.' As chiropractors have become
more scientically trained, however, they have gained increasing mainstream acceptance. James S. Gordon, Manifesto for a
New Medicine 172 (Addison-Wesley 1996).
23Diagnosis in TCM is based on history, on observation of the body (especially the tongue), on palpitation, and on pulse
diagnosis, an elaborate procedure requiring considerable skill and experience. Treatment involves dietary change, massage,
medicinal teas and other preparations made primarily from herbs but also including animal ingredients, and acupuncture. The
Chinese herbal pharmacopeia is vast, with many plants now under serious scrutiny by Western pharmacologists. Weil, supra
note 20, at 242.
24Ayurveda is one of the oldest systems of medicine, but has only recently become widely available in the West. Practitioners
diagnose by observing patients, questioning them, touching them, and taking pulses. With this information the practitioner
is able to assign patients to one of three major constitutional types and then to various subtypes. This classication dictates
dietary modications and selection of remedies. Ayurvedic remedies are primarily herbal, drawing on the vast botanical wealth
of the Indian subcontinent, but may include animal and mineral ingredients, even powdered gemstones. Other treatments
include steam baths and oil massages. Weil, supra note 20, at 239.
25Weil, supra note 20, at 239, 242.
7the proper regulatory channels and become conventional, others will appropriately be discarded. Found in
the shadier parts of this category are unapproved practices such as ozone therapy. This controversial therapy
utilizes an ozone generator, which creates a toxic form of oxygen to kill fungal and viral infections. Origi-
nally presented as an alternative and less invasive cancer therapy26 and more recently touted as a potential
treatment for AIDS27, ozone therapy is generally considered dangerous. According to FDA, [T]he machine
is unapproved, dangerous and has caused at least three deaths... when patients received extreme doses.28
Category (3) contains alternative practices that are relatively harmless, but are probably the hardest to
examine scientically because they tend to be more spiritual in nature. Some examples include religious
healing, crystal healing and guided imagery therapy. These types of medicines probably present few or no
safety concerns, but are also the least promising in terms of potential benet on a large scale.
Category (4) is not really alternative medicine, but phony alternative medicine and includes the malpractice
or abuse of it. The particular concern with these types of products is that they often profess to be natural
and therefore safe, but are consumed in such concentrated doses that they are toxic and even deadly. This
category of phony alternative medicine casts doubt upon the real medicines of Category (1). Basic health
fraud could also be included in this category.
While FDA or anyone else could certainly devise a dierent taxonomy for alternative medicine, the point is
that some division must be made. Without any categorization, discussion of FDA policy toward alternative
medicine is nonsensical, for it would clearly be ridiculous to treat TCM, with its two-thousand year old
history, in the same manner as a newfangled device like an ozone generator. A realistic view of alternative
26Michael H. Cohen, Holistic Health Care: Including Alternative and Complementary Medicine in Insurance and Regulatory
Schemes, 38 Ariz. L. Rev. 83, 119 (1996).
27Danny Westneat, Armed with Vitamins, And Now a Gun{FDA Foe Becomes Folk Hero, The Seattle Times, July 4, 1995,
at A1.
28Id.
8medicine includes a recognition of the expansiveness of the alternative medicine and its diculties, as well
as an attempt to create meaningful subdivisions for policy analysis.
B. Alternative Medicine Is Not Health Fraud.
There is an obvious reason why images of alternative medicine get tangled up in images of quackery: Since
both promote unapproved therapies, how are the good to be separated from the bad? While it may be
dicult to distinguish Category (4) products from Category (1) products, FDA must put forth the eort.
If FDA takes a realistic look at health fraud and alternative medicine, it might nd that the intersection of
the two are not so large. According to FDA, teenagers and the elderly are the chief targets for health fraud
promoters.29 According to the New England Journal of Medicine study30, however, it is mostly individuals
between the ages of twenty-ve and forty-nine with relatively higher levels of income and education who
are using alternative medicine. The people using alternative medicine in America are mostly those who will
spend the time and resources to learn more about their health so that they may take a more active role in
improving it. While FDA will always need to crack down on health fraud, it needs to separate that issue
from alternative medicine.
C. FDA's False Self-Conception of Being Encouraging Toward the Development of
Alternative Medicine
FDA cites as evidence of its open-mindedness, exibility and ability to adapt to the challenge of alterna-
29Guide, supra note 19.
30Eisenberg, supra note 2.
9tive medicine the IND (investigational new drug) process and the IDE (investigational device exemption)
process31. In Senate testimony on access to medical care, Jerrold Mande, Executive Assistant to the Com-
missioner of Food and Drugs, explained, FDA's exibility and open-mindedness in seeking new ways to
help patients are [demonstrated by] the INDs for thalidomide{a product with a well-known history. While
thalidomide is hazardous when used during pregnancy, it may be helpful for a variety of dierent indica-
tions. Despite the initial absence of a sponsoring company, FDA worked with individual investigators to
make promising strides in the safe use of thalidomide to treat severe canker sores in AIDS patients [and
several other hopeless diseases].32 While opening access to various untested remedies for life-threatening
diseases when nothing else will work is certainly a good idea, particularly for Category (2) therapies, its
usefulness for the development of alternative medicines in Category (1) is slim.
Mande also boasts as evidence of FDA being instrumental in addressing the new and varied challenges posed
by alternative and complementary products the reclassication of acupuncture needles from a Class III to
a Class II medical device33. While FDA is certainly moving in the right direction, one cannot help ques-
tioning why that step has taken so long in light of the device's history of use that is many times longer
than the history of the United States. Mande also cites as evidence of FDA's instrumentality the fact that
most botanical products are legally marketed as dietary supplements without any impediments by FDA. To
credit itself for not interfering with most botanicals, however, is either unrealistic or downright dishonest.
As discussed in Section II, DSHEA was passed for the very purpose of removing from FDA the control it
did not want to surrender.34
D. The Current Regulatory Climate Is Inadequate for Many Types of Alternative Medicines.
31Medical Treatment: Testimony Before the Sen. Comm. on Labor and Human Resources, 105th Cong. (1996)(testimony
of Jerrold Mande, Executive Assistant to the Commissioner of Food and Drugs).
32Id.
33Id.
34FDA is however, in the process of developing a guidance document on botanicals. Mande, supra note 32.
10Because Category (1) alternative medicines are premised on philosophies that dier from conventional Amer-
ican medicine, they cannot develop within the conventional regulatory framework. FDA presents itself as
open-minded and even-handed toward alternative medicine in that it wants patients to have early access to
novel medical interventions, regardless of whether they are conventional, 'alternative,' or 'complementary.'
35 From the perspective of FDA, [I]t doesn't matter whether the product or treatment is labeled alternative
or falls under the auspices of mainstream American medical practice... It must meet the agency's safety
and eectiveness criteria before being allowed on the market.36 The problem with this so-called unbiased
approach to alternative medicine is that it fails to acknowledge the fact that many are based on philosophies
of medicine that are fundamentally dierent from the disease treatment philosophy of conventional medicine.
For instance, several alternative medicines follow the premise that a person's body has natural healing powers
and emphasis should be placed on prevention through enhancing these powers.37 Amidst the backdrop of
conventional medicine, however, FDA's regulatory framework has developed as a system eager for curative,
rather than preventive therapies. For example, Robert McCaleb points to the dearth of preventive medicine
as evidence of this in tandem development:
The American health care system has been characterized as a 'disease treatment system' because of the
conspicuous absence of approved preventive medicines... Preventive medicine, frequently touted as a key to
lowering heath care costs is thwarted by FDA's current regulatory policies... In the U.S. we have no legitimate
place in our regulatory framework for preventive medicines. After over 50 years of drug regulation, the FDA
has not approved a single over-the-counter drug for internal use in the prevention of any major disease. The
only non-prescription preventive medicines approved by FDA are uoride toothpaste, sunscreen and motion
sickness pills. During the 20 year process of 'reviewing' OTC ingredients, FDA never even established a
category in which preventive medicine products could be considered. We have a few prescription preventive
35Id.
36Guide, supra note 19.
37See Weil, supra note 21.
11drugs, such as those to treat hypertension and lower blood cholesterol, but these are available only to those
with a pathological condition. Our only other preventive medicines, like vaccines and antimalarials, are also
prescription only....3839
Another example of how FDA fails to recognize alternative medicine's alternative basic principles is its attitude
toward clinical trials. In an FDA Consumer article, FDA recommends that anyone wishing to explore alternative
therapies should participate in one of the currently ongoing clinical trials, including studies of: acupuncture to
treat depression, attention-decit hyperactivity disorder, osteoarthritis, and various pains; Ayurvedic herbals for
Parkinson's disease; biofeedback for diabetes and various pains; electric currents for tumors; and imagery therapy
for asthma and cancer.40 This seemingly harmless recommendation illustrates several points. First, none of these
trials were designed to examine the preventive aspects of alternative care, which demonstrates a blatant dismissal
of perhaps the most important part of alternative medicine. Second, the testing of preventive therapies for curative
properties sets up them for failure, which will cast doubt upon their usefulness for more preventive purposes.
Third, using the conventional paradigm of trying to isolate specic treatments for specic indications disregards the
holistic, integrative and patient-specic nature of many forms of alternative medicine.
Even when the philosophical dierences are placed aside, there are logistical problems in obtaining the kind
of scientic evidence required for conventional medicines. Acupuncture provides a good example. To test
the ecacy of a therapy, researchers use patients with all the same medical diagnosis.41 This conventional
method might not work for acupuncture, which oers treatment based on all facets of an individual, rather
than just the symptoms of disease.42 The placebo-controlled, double-blind study design of Western research
38McCaleb, supra note 17.
39Recently, FDA approved another preventive OTC drug, bentoquatam, which protects against poison ivy. See Ivy
Fleischer Kupec, FDA Approves First Drug That Protects Against Poison Ivy, FDA Answers, Aug. 28, 1996. See
http://www.fda.gov/bbs/topics/ANSWERS/ANS00757.
41Acupuncture (Can This Ancient Treatment Help to Control Problems Like Pain and Addiction?), Consumer Reports,
January 1994 at 54-59.
42Id.
12causes problems for the testing of acupuncture.43 In a double-blind study, neither the subject nor the inves-
tigator knows which individuals are receiving treatment.44 Because an acupuncturist must know where, at
what angle and with what motion to insert the needles, designing a double blind study would be impossi-
ble.45 The inevitable result is a long history of successful use, but limited scientic evidence of ecacy
to satisfy conventional standards.
Homeopathy is an important example of alternative medicine not tting into the conventional regulatory
paradigm because it is the one area where FDA did recognize the incompatibility and correctly responded.
This section will only mention the diculties of making homeopathy function within the conventional reg-
ulatory system; Section IV.A.4 will detail FDA's regulatory responsiveness to the dilemma. Homeopathy is
based on German physician Samuel Hahnemann's law of similars. Under this theory of medicine, extremely
small doses of substances that would cause symptoms similar to those of the disease in a healthy person
actually cure an ailing person of the disease. According to Dana Ullman, President of the Foundation for
Homeopathic Education and Research and spokesperson for the National Center for Homeopathy, homeo-
pathic products have to be treated dierently from conventional products, 'Like acupuncture, homeopathy
is a dierent system of treating people... It doesn't treat diseases per se, but treats people who are ill. Doing
research on these methods requires a dierent type of research design.'46
Because alternative medicines are so dierent in philosophy from conventional medicine, the conventional
regulatory climate is inappropriate for them. FDA must shift its mind-set to recognize these dierences
before it can meaningfully and realistically address the diculties of alternative medicine.
43Id.
44Id.
45Id.
46Andrew A. Skolnick, FDA Petitioned To 'Stop Homeopathy Scam', 272 The Journal of the American Medical Asso-
ciation 1154 (1994).
13IV. FDA's Inchoate Policies on Alternative Medicine and Their Impact
As explained in Section III, FDA's reluctance to accept the reality that to the extent that alternative
medicines are premised on alternative philosophies, applying the conventional regulatory framework is simply
inappropriate. By not making some paradigmatic shift, FDA has been conned to trying to force alternative
medicine into the conventional regulatory system or just to disregarding it. This kind of unthinking action
and inaction demonstrates a failure to meet the challenges of alternative medicines, and sends confusing
signals to the public about the safety and desirability of alterative medicine.
A. FDA's Inconsistency on Alternative Medicine.
1. A Control-Freakish FDA.
FDA's relentless eorts to preserve supreme control over vitamins and other dietary supplements reveal the
control-freak side of the Agency and indicate an aversion toward alternative medicine based mostly on an
unwillingness to lose any regulatory control, rather than something more substantive. The history behind
the passage of DSHEA is a clear illustration of FDA's insistence on maintaining control over vitamins and
other dietary supplements with blatant disregard for public sentiment, Congress, and the courts.
The Committee Report on DSHEA details this history well47: In the decades preceding DSHEA, FDA had
developed an increasingly aggressive approach toward regulating supplements. In 1962 FDA issued regu-
47DSHEA Report, supra note 14.
14lations setting minimum and maximum levels for supplements, but eventually withdrew them in the face
of strong citizen protest. Between 1966 and 1973 FDA attempted to classify vitamins as over-the counter
(OTC) drugs if the product surpassed 150% of the Recommended Daily Allowance (RDA). Congress blocked
FDA with the Proxmire/Rogers amendment to the FD&C Act. Refusing to take the cue from Congress,
FDA attempted to regulate vitamins in the late 1970s on the basis that because they were toxic, their po-
tencies could be regulated. The FDA's attempt to get around the Amendment, however, was rebued by
the federal courts. Still determined to assert control over vitamins, in 1980 FDA issued a proposed OTC
drug monograph for vitamins and minerals which purported to deal only with potencies above the RDA,
but implicitly imposed potency limits. Only after strong public opposition did FDA withdraw the proposal.
Continuing its obsession with controlling vitamins, FDA formulated a 'food additive theory' to ban the sale
of supplements that made no health claims: Essentially, the theory was that any ingredient added to a cap-
sule or tablet rendered the resulting dietary supplement a food additive because the ingredient was added
to the capsule or tablet. Under this theory, FDA could not lose, as it needed only to furnish an adavit
from one of its scientists stating that experts generally did not regard the product as safe. The actual safety
of the product was never at issue.48 FDA's creative construction of the law to prevent marketing of dietary
supplements was denounced by the federal courts. In two 1993 cases49 FDA argued that the black currant
oil in capsules of black currant oil constituted a food additive to the capsule and was of questionable safety.
In both cases the courts held that the black currant oil could not be considered a food additive, so the
manufacturer did not have the burden of proving that the oil was generally regarded as safe (GRAS). In
Two Plastic Drums, the court expounded upon the ridiculousness of FDA's position, which taken to the
extreme would classify every component of food as a food additive, and chided, The only justication for
48DSHEA Report.
49See U.S. v. Two Plastic Drums... Black Currant Oil..., 984 F.2d 814 (7th Cir. 1993) and
U.S. v. Twenty-nine Cartons of * * * An Article of Food, Etc., 987 F.2d 33 (1st Cir. 1993).
15this Alice-in-Wonderland approach is to allow the FDA to make an end-run around the statutory scheme
and shift to the processors then burden of proving the safety of a substance in all circumstances.50
Congress nally put an end to FDA's control with the passage of DSHEA. The Act is the most recent and
probably the most important attempt to check FDA authority in the area of alternative medicine because
the vitamins and herbs used in many forms of alternative medicine are considered dietary supplements under
the Act.51 DSHEA, which was specically proposed to stop FDA from removing many herbs and other sup-
plements from the market or regulating them as drugs, elicited the greatest amount of constituent response
of any bill in history of Congress.52
This history depicts FDA's opposition to alternative medicine as a by-product of its desire to retain as much
control as possible.
2. A Tough Cop FDA.
A widely publicized FDA raid in 1992 revealed a tough cop side to FDA and led many people to believe that
the agency was on a crusade to stomp out alternative medicine. In the high Kent, Washington raid, more
than two dozen federal and state law enforcement ocers, including FDA agents, stormed an alternative
medicine clinic and pharmacy in the same shopping plaza. The clinic was run by Dr. Jonathan Wright, who,
with a college degree from Harvard and a medical degree from the University of Michigan, does not t the
stereotype of a medical quack. After eight months of sifting through the clinic's garbage cans, FDA ocers,
50Two Plastic Drums, 984 F.2d 814 at 819.
5121 U.S.C.A. x321() (1997).
52Alternative Medicine Oers Answers for Health Reform, Biotech Financial Reports, May 1995.
16accompanied by armed police ocers in ak jackets, seized $100,000 worth of medicines and equipment.53
Some of the items seized included injectable vitamins, minerals, glandular extracts, photocopies of patient
records, and devices that measure the electromagnetic energy of the body to test people for allergies.54
The raid created an world-wide blaze of negative publicity for FDA. More than two thousand letters were
faxed to the White House within 24 hours sharply criticizing the FDA action. Newspapers were lled with
articles denouncing the SWAT-like team of U.S. Food and Drug Administration agents... [who] eectively
terrorized the sta and patients.55 In a testimony on Regulatory Flexibility Proposals in 1995, this incident
was even used as an example of the general need to increase checks on regulatory powers56. According to
that testimony, FDA public aairs ocials explained that they had 'to play a little rough to send a message
to the whole industry.'57 FDA Commissioner David Kessler defended, 'The search uncovered the illegal and
dangerous products that the FDA and sheris believed were present at the clinic.'58
3. An Indierent FDA.
In sharp contrast to FDA's super-cop enforcement tactics, a quick browse through a health food store or
Chinatown will reveal an FDA with little interest in enforcement. Health food stores are rife with products
that are either labelled with specic health claims or sold in juxtaposition to publications detailing such
health benets. Similarly, stores in Chinatown regularly sell TCM herbal products, with labelling ranging
from general statements of improving energy to bold claims of curing diseases such as AIDS. The FD&C Act
53Westneat, supra note 27.
54Id.
55Questionable Tactics{Motives Suspect in Health Store Raids (Editorial), The Fort Worth Star-Telegram, August 21,
1992.
56Regulatory Flexibility Proposals: Testimony Before the House Judiciary Subcomm. on commercial and Administrative
Law of the House Comm. on the Judiciary, 104th Cong. (February 3, 1995)(testimony of Susan Eckerly, Deputy Director of
Economic Policy and Walker senior fellow in economic policy at The Heritage Foundation.)
57Id.
58Id.
17prohibits dietary supplement statements that claim to diagnose, mitigate, treat, cure, or prevent a specic
disease or class of diseases.59 Additionally, publications used in connection with the sale of a dietary supple-
ment to consumers when sold next to the products are considered labelling.60 Nonetheless, these operations
continue.
4. A Flexible FDA.
The most important example of FDA exibility has been in the area of regulation of homeopathy. Though
clearly considered alternative medicine, homeopathy holds a special place in the regulatory framework be-
cause the chief sponsor of the 1938 FD&C Act was a homeopathic physician who included in the statutory
denition of drug, homeopathic drugs.61 FDA, however, regulates homeopathic drugs dierently from other
drugs in several ways: (1) homeopathic drug manufacturers are deferred from submitting NDAs, (2) home-
opathic drugs are exempt from GMP requirements concerning expiration dating and from nished product
testing for identity and strength, (3) homeopathic drugs in solid oral dosages must be imprinted with the
manufacturer's name and indicate that the drug is homeopathic (this is dierent from the requirement that
non-exempt conventional products identify the active ingredient and dosage strength as well as the manu-
facturer), (4) some homeopathic drugs are exempt from the 10% alcohol limit on conventional drugs.62
According to Edward Miracco, a consumer safety ocer with FDA's Center for Drug Evaluation and Re-
search, 'The reasoning behind [the dierence] is that homeopathic products contain little or no active ingre-
dients... From a toxicity, poison-control standpoint, [the active ingredient and strength] was deemed to be
unnecessary... Overall, the disparate treatment has been primarily based on the uniqueness of homeopathic
5921 U.S.C.A. x343(r)(6)(1997).
6021 U.S.C.A. xx343(r)(6) & 343-2 (1997).
61Isadora B. Stehlin, Homeopathy: Real Medicine or Empty Promises?, FDA Consumer, December 1996 [hereinafter Home-
opathy]. See also 21 U.S.C.A. x321(g)(1)(1997).
62Id.
18products, the lack of any real concern over their safety because they have little or no pharmacologically active
ingredients, and because of agency resources and priorities.63 This example of FDA exibility provides hope
for the Agency's willingness and capacity successfully to handle the challenges of alternative medicine.
B. The Impact of FDA's Inconsistency
With such varied responses to alternative medicine, dierent sectors of the population interpret FDA action
quite dierently. Some supporters of alternative medicine present a conspiracy theory:[G]overnment ocials
are in unholy alliance with the medical establishment and pharmaceutical industry, which would suer enor-
mous economic loss if people stayed healthy through good nutrition or could be cured with non-patentable
drugs and other substances appearing commonly in nature.64
Pharmaceutical manufacturers, however, seem to take a dierent view of FDA on alternative medicine. One
editorial in Pharmaceutical Executive ponders:
I have often questioned why so many alternative medicine practitioners get away with selling what seem to
be drugs that haven't passed any FDA tests for safety and ecacy. So I've been heartened this past year
by some examples of FDA intervention [such as FDA's raid of Dr. Stanislaw Burzynski], who for years has
been peddling a 'miracle cure' for cancer... But FDA is both slow and timid... I understand FDA's caution
in the matter. FDA is, after all, a political agency, and it faces potent opposition whenever it impedes the
alternative medicine constituency. Conversely, FDA freely condemns pharmaceutical companies for allegedly
promoting an FDA-approved medicine for purposes outside specic indications. But then, nobody has ever
seen a public demonstration of support for a pharmaceutical company, and FDA Commissioner Dr. David
Kessler, for one, never expects to.65
63Id.
64Questionable Tactics, supra, note 61.
65Roof & Remedies None of the Alternative Medicines in Today's Market Are New, Pharmaceutical Executive, November
1, 1996.
19The net result is that no one really knows where FDA stands on alternative medicine, but that's mostly because FDA
itself is unsure. This uncertainty creates a real road block to the goal of making alternative medicine a safe and
viable health care choice for Americans. People cannot make intelligent choices in health care without sucient
information. FDA's ambiguous-leaning-on-the-negative-side bias against alternative medicine contributes to a
vicious cycle: As long as FDA appears poised to block alternative medicines, limited funding will go into its research.
Without such research, many of these therapies will never achieve the scientic backing required to satisfy FDA.
In testimony before the Senate concerning DSHEA, Robert McCaleb of the Herb Research Foundation described
this dilemma as it relates to the herbal remedies industry:
The regulatory lockout of natural remedies has not only impeded the herbal products industry, denied
valuable remedies to the elderly and minorities, but has crippled natural products research in our Universities
and hospitals. The elds of Pharmacognosy (the study of drugs of natural origin) and other academic pursuits
involving the study of medicinal plants have declined alarmingly in the U.S. American scientists, once at
the forefront of this type of research, are lagging behind their European and Japanese counterparts, further
reducing the likelihood of American discoveries of useful new medicines from plants. This is of concern to
the academics themselves and should be to policy makers concerned with international competitiveness.66
66McCaleb, supra note 17.
20In addition to hampering research in the area of alternative medicines, this confusion also contributes to the safety
problems. The more people think FDA is regulating, the less individual thought they will put into the safety of
the products they use. If there is a signicant disparity between the two, risk of people being injured will rise.
For example, ephedrine, an amphetamine-like stimulant, has been marketed as a 'natural' substance to promote
euphoria or increase energy,' under names like Cloud 9... , Ultimate Xphoria and Herbal Ecstasy.67 Many people
who used these products for the high ended up with strokes, heart attacks, or psychotic episodes. Some people died.
Because herbal ephedrine is considered a dietary supplement, FDA did not regulate it. Whether public knowledge
of that fact would have averted any harm in this example is unclear, but eliminating the guessing of what FDA is
regulating could only be helpful.
A related problem is that such incidents trigger a blanket fear of herbal preparations, unnecessarily ham-
pering development for legitimate uses. TCM has used herbals containing ephedrine, known as ma huang,
for thousands of years to treat asthma and low blood pressure. These recent episodes serve only to generate
thoughts that TCM is therefore dangerous and should not be used. As Dr. James S. Gordon, Chairman of
the Program Advisory Council of the OAM, explained, Ma huang should be used intelligently [for certain
indications], not indulged in, or promoted indiscriminately, for the 'high' it might give.68 FDA needs to de-
velop a sound policy toward alternative medicine that alerts customers to the risks of such products without
destroying interest in using them for healthful purposes.
The guessing game of how FDA will react to a particular medicine, clinic or practitioner hinders the devel-
opment of alternative medicine and prevents it from becoming a safe and reliable health care option.
V. Regulatory Flexibility
68James S. Gordon, Unconventional Medicine Deserves Mainstream Attention, The Washington Post, October 6, 1996 at
C4.
21While many alternative medicines are conceptually dierent from conventional medicine, that reality does
not make them wholly incompatible with the current regulatory structure. Neither giving up on alternative
medicine because it does not t into the conventional framework, nor creating an entirely new framework
is necessary. FDA just needs to add exibility to the current system through exemptions and adjusted
standards. In deciding what alterations to make, FDA can turn to several sources for guidance.
Much of what we term alternative medicine in the United States is conventional medicine in other countries.
Foreign models of regulation of certain therapies would be helpful in providing some guidance. For instance
herbal medicine is highly developed in Germany. Although herbal product development is mostly motivated
by demand, Germany's encouraging regulatory environment plays no small role.69 In Germany approval
of herbal drugs is based not only on study results, but also on clinical and pharmacological literature.70
Germany's process has been described as requiring 'reasonable certainty' rather than 'absolute proof' of
safety and ecacy which the FDA requires.71 Under current FDA standards, the drug approval process
costs are too high to provide any nancial incentive to develop herbal drugs.72 By studying the German
system, FDA can work within its current framework to accommodate herbal and perhaps other alternative
medicines. Additionally FDA could alter it regulations so that more foreign studies could be used to satisfy
the standards for scientic evidence.
FDA should also consider how the regulatory exemptions permitted for homeopathic drugs might work for
69Edgar R. Cataxinos, Regulation of Herbal Medications in the United States: Germany Provides a Model for Reform, 1995
Utah L. Rev. 561, 578 (1995).
70Id. at 579.
71Id.
72Id.
22other types of alternative medicine. The main reason that FDA even bothered to nd a way to t home-
opathic drugs within its regulatory scheme was probably because the statute made it inescapable. FDA
needs to nd similar solutions for other types of alternative medicine. As described in Section IV.A.4, FDA
decided that as long as the safety concerns for homeopathic drugs were low, it would not worry as much
about the lack of adequate ecacy evidence for homeopathic drugs. Why not apply the same reasoning to
other bodies of medicine? The easiest ones to start with would be those that already have pharmacopoeias,
such as TCM. As explained in Section III.A, the forms of alternative medicine with the greatest potential for
Americans tend to be preventive in nature and safe because they are natural or used in very low dosages, as
in homeopathy. According to Dr. David Eisenberg, director of the Center for Alternative Medicine Research
at Beth Israel Hospital in Boston, 'I think that by and large the evidence is that many herbal products
are safe.'73 By providing certain exemptions, FDA could make a more exible regulatory environment and
increase the availability of drugs that are relatively safe, but whose ecacy has less scientic backing. FDA
could also accept more foreign studies. As long as the drugs are clearly labelled as alternative, people will
know that they are mostly safe, but they will have to do some individual experimentation of their own to
determine just how useful the products will be to them. Collaboration with OAM would also be helpful in
this area.
In adding exibility to the regulatory climate, FDA should resist the temptation to keep as much control as
possible. As the practice of alternative medicine becomes increasingly regulated by state law, the need for
FDA to do more than ensure the safety of products diminishes.
By building additional exibility into the current regulatory regime, FDA can sensibly accommodate alter-
native medicine without compromising the standards of conventional medicine.
73Kolata, supra note 67.
23VI. Conclusion.
Alternative medicine has already established a role for itself in the health care of many Americans. FDA, how-
ever, has been slow to develop a meaningful and coherent regulatory response to this growing phenomenon.
Reluctant to change its mind-set, FDA acts under the mistaken belief that the current regulatory scheme
can accommodate any alternative medicine that will be useful to the public. Because of their conceptual
and philosophical dierences from conventional medicine, however, many alternative therapies simply cannot
meet the demands of the current regulatory system. This reality does not imply that such medicines are not
valuable. While it is true that many practices that are labelled alternative are nothing more than health
fraud and often dangerous, there are also many medicines with great potential to improve how Americans
think about and use medicine. A coherent policy toward alternative medicine and a more exible regulatory
scheme are required of FDA if Americans are to be given the freedom to choose dierent forms of health
care safely and wisely.
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